Table 4.
Hazard ratios (95% confidence interval) of risk of all-cause mortality by uPCR, uACR, uAPR, and uNAP by the concordance between uPCR and uACR and uAPR above or below 40% (based on imputation dataset).
| N | Case | Crude model (95% CI) | Model 1 (95% CI) | Model 2 (95% CI) | Model 3 (95% CI) | |
|---|---|---|---|---|---|---|
| Overall | ||||||
| uPCR (per double increase) | 2904 | 657 | 1.42 (1.37, 1.47) | 1.42 (1.37, 1.47) | 1.43 (1.38, 1.48) | 1.29 (1.24, 1.35) |
| uACR (per double increase) | 1.22 (1.19, 1.25) | 1.22 (1.19, 1.25) | 1.23 (1.19, 1.26) | 1.12 (1.09, 1.16) | ||
| uAPR (per 10% increase) | 1.09 (1.05, 1.12) | 1.08 (1.05, 1.12) | 1.08 (1.05, 1.12) | 1.02 (0.98, 1.06) | ||
| uNAP (per double increase) | 1.56 (1.50, 1.62) | 1.56 (1.50, 1.63) | 1.57 (1.51, 1.63) | 1.41 (1.34, 1.49) | ||
| Concordance proteinuria | ||||||
| uPCR (per double increase) | 2383 | 497 | 1.43 (1.37, 1.48) | 1.43 (1.37, 1.49) | 1.44 (1.38, 1.50) | 1.30 (1.24, 1.37) |
| uACR (per double increase) | 1.28 (1.24, 1.32) | 1.28 (1.24, 1.32) | 1.28 (1.24, 1.32) | 1.19 (1.14, 1.23) | ||
| uAPR (per 10% increase) | 1.19 (1.15, 1.24) | 1.19 (1.14, 1.24) | 1.19 (1.15, 1.24) | 1.11 (1.06, 1.16) | ||
| uNAP (per double increase) | 1.54 (1.47, 1.61) | 1.54 (1.47, 1.61) | 1.55 (1.48, 1.62) | 1.38 (1.30, 1.46) | ||
| Non-albumin predominant proteinuria | ||||||
| uPCR (per double increase) | 363 | 150 | 1.69 (1.48, 1.92) | 1.68 (1.46, 1.93) | 1.70 (1.47, 1.96) | 1.57 (1.32, 1.87) |
| uACR (per double increase) | 1.15 (1.05, 1.26) | 1.15 (1.05, 1.26) | 1.16 (1.05, 1.27) | 1.07 (0.96, 1.19) | ||
| uAPR (per 10% increase) | 0.83 (0.71, 0.97) | 0.84 (0.72, 0.99) | 0.85 (0.72, 1.00) | 0.83 (0.70, 0.98) | ||
| uNAP (per double increase) | 1.70 (1.50, 1.93) | 1.70 (1.49, 1.95) | 1.73 (1.50, 1.98) | 1.61 (1.36, 1.90) | ||
| uAPR < 40% | ||||||
| uPCR (per double increase) | 1683 | 320 | 1.77 (1.67, 1.87) | 1.76 (1.66, 1.88) | 1.77 (1.66, 1.88) | 1.64 (1.51, 1.79) |
| uACR (per double increase) | 1.44 (1.36, 1.51) | 1.44 (1.36, 1.51) | 1.44 (1.36, 1.52) | 1.25 (1.17, 1.34) | ||
| uNAP (per double increase) | 1.79 (1.69, 1.90) | 1.79 (1.69, 1.91) | 1.79 (1.69, 1.91) | 1.67 (1.54, 1.82) | ||
| uAPR ≥ 40% | ||||||
| uPCR (per double increase) | 1221 | 337 | 1.42 (1.33, 1.51) | 1.42 (1.33, 1.51) | 1.43 (1.34, 1.52) | 1.27 (1.18, 1.37) |
| uACR (per double increase) | 1.37 (1.29, 1.45) | 1.37 (1.29, 1.45) | 1.38 (1.30, 1.47) | 1.24 (1.16, 1.33) | ||
| uNAP (per double increase) | 1.45 (1.37, 1.55) | 1.45 (1.36, 1.55) | 1.46 (1.37, 1.56) | 1.28 (1.19, 1.39) | ||
Model 1: Adjusted gender, diabetes, hypertension, cardiovascular disease and cancer.
Model 2: Adjusted gender, diabetes, hypertension, cardiovascular disease, cancer, ACEI, ARBs, and anti-platelet agents.
Model 3: Adjusted gender, diabetes, hypertension, cardiovascular disease, cancer, ACEI, ARBs, anti-platelet agents, eGFR, hemoglobin, and glucose.
ACEI angiotensin-converting-enzyme inhibitors, ARBs angiotensin receptor blockers, eGFR estimated glomerular filtration rate, uAPR urine albumin-to-protein ratio.